Nav: Home

Moffitt researchers identify new target to reduce risk of GVHD

February 05, 2018

TAMPA, Fla. - Stem cell transplants can cure patients with high-risk leukemia or lymphoma. Graft-versus-host disease (GVHD) is a potentially life-threatening side effect that occurs when the donor's immune cells attack the recipient's normal tissues. Moffitt Cancer Center researchers are trying to identify new drug targets to reduce the risk of GVHD. Their new study, published last week in the Proceedings of the National Academy of Sciences, shows a drug that targets the protein JAK2 may reduce the risk of GVHD.

The goal of stem cell transplants is to replenish the bone marrow and eliminate residual cancer using the donor's immune cells. However, in some cases the donor's white blood cells mount an immune response against the recipient's normal tissues. It is estimated that GVHD affects up to half of all stem cell recipients. The symptoms of GVHD can vary from mild to severe and include skin inflammation and rash, liver inflammation, jaundice, gastrointestinal problems, pain, and fatigue. Despite modern immune suppressive medications, death is possible when severe GVHD occurs.

The goal of GVHD treatment is to block the donor immune cells from targeting the body's normal cells, while at the same time maintaining the ability of the donor cells to target cancer cells for destruction. GVHD is commonly treated with drugs that suppress the immune system, such as glucocorticoids, but the scientific community is trying to find better alternatives with less side effects.

"An effort to identify selective immune suppression whereby GVHD is reduced and the antitumor activity of the graft is preserved is key to improving the success of blood and marrow transplantation," said Brian C. Betts, M.D, lead study author and associate member of the Blood and Marrow Transplant and Cellular Immunotherapy Department at Moffitt.

The protein JAK2 is believed to be involved in the development of GVHD. In collaboration with researchers from the Medical University of South Carolina, the Moffitt research team wanted to confirm the link and assess if blocking JAK2 could reduce the occurrence of GVHD. They performed experiments with mice that were genetically engineered to be missing the JAK2 gene. They discovered that JAK2 regulates several of the immune cell mechanisms that lead to GVHD. They also showed that donor cells missing the JAK2 gene induced GVHD less than normal donor cells, and the genetically modified cells were still able to target tumor cells for destruction.

These observations suggest drugs that target JAK2 may prevent GVHD and still allow the donor cells to target cancer cells. The researchers confirmed this by transplanting normal stem cells into recipient mice and treating the mice with the drug pacritinib that inhibits JAK2. They discovered that pacritinib reduced the number of immune cells responsible for GVHD and the number of mice that died from GVHD. Importantly, pacritinib did not inhibit the ability of the transplanted stem cells from targeting cancer cells for destruction. The Moffitt research team also discovered that pacritinib could protect mice from tissue graft rejection, suggesting this approach could be used to prevent kidney or liver transplant rejection.

These results suggest that pacritinib may be a potential drug option to prevent GVHD in stem cell recipients. Betts and his Moffitt colleague, Joseph Pidala, M.D., Ph.D., are investigating a phase 1/2 acute GVHD prevention trial combining pacritinib with standard immune suppression after stem cell transplant.
-end-
This study was supported by grants from the National Institutes of Health (R01 CA143812, R01 CA169116, and K08 HL11654701A1)

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,700 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.

H. Lee Moffitt Cancer Center & Research Institute

Related Immune Cells Articles:

Immunology: How ancestry shapes our immune cells
A genetic variant that is particularly prevalent in people of African ancestry confers protection against malaria.
Immune cells derived from specialised progenitors
Dendritic cells are gatekeepers of Immunity. Up to now dendritic cell subtypes were thought to develop from one common progenitor.
Comprehensive atlas of immune cells in renal cancer
Researchers from the University of Zurich have individually analyzed millions of immune cells in tumor samples from patients with renal cell carcinoma.
When liver immune cells turn bad
A high-fat diet and obesity turn 'hero' virus-fighting liver immune cells 'rogue,' leading to insulin resistance, a condition that often results in type 2 diabetes, according to research published today in Science Immunology.
New role for immune cells in preventing diabetes and hypertension
Immune cells which are reduced in number by obesity could be a new target to treat diseases such as type 2 diabetes and hypertension that affect overweight people, according to a collaborative study between the University of Manchester, Lund University and the University of Salford.
Why male immune cells are from Mars and female cells are from Venus
Michigan State University researchers are the first to uncover reasons why a specific type of immune cell acts very differently in females compared to males while under stress, resulting in women being more susceptible to certain diseases.
Immune therapy scientists discover distinct cells that block cancer-fighting immune cells
Princess Margaret Cancer Centre scientists have discovered a distinct cell population in tumours that inhibits the body's immune response to fight cancer.
Opioids produce analgesia via immune cells
Opioids are the most powerful painkillers. Researchers at the Charité -- Universitätsmedizin Berlin have now found that the analgesic effects of opioids are not exclusively mediated by opioid receptors in the brain, but can also be mediated via the activation of receptors in immune cells.
Oddly shaped immune cells cause fibrosis
Scientists at the Immunology Frontier Research Center (IFReC) at Osaka University, Japan, report a new group of monocytes they call SatM.
New system developed that can switch on immune cells to attack cancer cells
Researchers have developed an artificial structure that mimics the cell membrane, which can switch on immune cells to attack and destroy a designated target.

Related Immune Cells Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".